专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

US20160266121A1 ASSESSING THE RISK OF A MAJOR ADVERSE CARDIAC EVENT IN PATIENTS WITH CHEST PAIN 审中-公开
标题翻译：评估患者与主要疼痛患者的主要不良心脏事件的风险
公开(公告)号：US20160266121A1
公开(公告)日：2016-09-15
申请号：US15164205
申请日：2016-05-25
申请人： THE CLEVELAND CLINIC FOUNDATION
发明人： Stanley L. Hazen , Renliang Zhang
IPC分类号： G01N33/573
CPC分类号： G01N33/573 , C12Q1/28 , G01N33/6893 , G01N2333/908 , G01N2800/32 , G01N2800/50 , G01N2800/56
摘要： Methods for characterizing the near terns risk of experiencing a major adverse cardiac event in a patient presenting with chest pain are provided. In one embodiment the method comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained. from the patient. In another embodiment, the method comprises determining the level of MPO mass in a bodily sample obtained from the patient. In another embodiment, the method comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the patient. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, chlorotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation product. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a control value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from control population. Such comparison can also be used to determine the near term treatment of the patient.
摘要翻译：提供了表征患有胸痛的患者的主要不良心脏事件的近端子风险的方法。在一个实施方案中，该方法包括确定所获得的身体样品中髓过氧化物酶（MPO）活性的水平。来自病人。在另一个实施方案中，该方法包括确定从患者获得的身体样品中的MPO质量的水平。在另一个实施方案中，该方法包括确定从患者获得的身体样品中的一种或多种选择的MPO产生的氧化产物的水平。选择的MPO生成的氧化产物是二酪氨酸，硝基酪氨酸，氯酪氨酸，甲硫氨酸亚砜或MPO产生的脂质过氧化产物。然后将来自测试受试者的身体样品中的MPO活性，MPO质量或选择的MPO生成的氧化产物的水平与从MPO活性，MPO质量或选择的MPO产生的氧化产物的测量结果相关的对照值进行比较在从对照群体获得的可比较的身体样品中。这种比较也可用于确定患者的近期治疗。

32. 发明申请

US20160109448A1 MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE 审中-公开
公开(公告)号：US20160109448A1
公开(公告)日：2016-04-21
申请号：US14984072
申请日：2015-12-30
申请人： THE CLEVELAND CLINIC FOUNDATION
发明人： Stanley L. Hazen , Renliang Zhang
IPC分类号： G01N33/573 , A61K31/616
CPC分类号： G01N33/573 , A61K31/616 , C12N1/28 , C12Q1/28 , C12Y111/01007 , G01N2333/908 , G01N2800/32 , G01N2800/324 , G01N2800/50 , G01N2800/52 , G06F19/00 , G06Q50/22 , G16H50/30 , Y02A90/22 , Y02A90/26
摘要： Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a predetermined value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from the general population or a select population of human subjects. Such comparison characterizes the test subject's risk of developing CVD.

33. 发明申请

US20150037905A1 RISK MARKERS FOR CARDIOVASCULAR DISEASE 审中-公开
标题翻译：心血管疾病危险标志
公开(公告)号：US20150037905A1
公开(公告)日：2015-02-05
申请号：US14275307
申请日：2014-05-12
申请人： THE CLEVELAND CLINIC FOUNDATION
发明人： Stanley L. Hazen , Michael Kinter , Marc S. Penn , Jonathan Smith , Lemin Zheng
IPC分类号： G01N33/561 , C07K16/18
CPC分类号： G01N33/561 , C07K16/18 , G01N33/6893 , G01N33/92 , G01N2333/775 , G01N2800/32
摘要： Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotein A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy.
摘要翻译：本文提供用于确定受试者，特别是人类受试者是否处于发展，具有或经历心血管疾病并发症的风险的方法，以及治疗由目前的心血管疾病风险的方法鉴定的受试者的方法。在一个实施方案中，该方法包括确定来自受试者的身体样品中一种或多种氧化的载脂蛋白A-1相关生物分子的水平。此外，提供了用于本方法的试剂盒和试剂。还提供了用于监测受试者心血管疾病状态或治疗剂对心血管疾病受试者的影响的方法。这种方法包括测定在受试者随时间或治疗之前或之后取自受试者的身体样品中一种或多种氧化的载脂蛋白A-1相关分子的水平。

34. 发明授权

US12055535B2 Trimethylamine compounds as risk predictors of cardiovascular disease 有权
公开(公告)号：US12055535B2
公开(公告)日：2024-08-06
申请号：US16781409
申请日：2020-02-04
申请人： The Cleveland Clinic Foundation
发明人： Stanley L. Hazen , Zeneng Wang , Bruce S. Levison
IPC分类号： G01N33/48 , G01N33/483 , G01N33/49 , G01N33/493 , G01N33/68 , G01N33/92 , H01J49/00
CPC分类号： G01N33/49 , G01N33/493 , G01N33/6893 , G01N33/92 , H01J49/0036 , G01N2800/32 , G01N2800/323 , G01N2800/50 , G01N2800/52 , G01N2800/56 , Y10T436/174614
摘要： Methods of characterizing a test subject's risk of having or developing cardiovascular disease are provided. The methods include using an analytic device to determine levels of choline-related trimethylamine-containing compounds such as trimethylamine N-oxide, choline, or betaine in a biological sample obtained from the subject and comparing the levels of the choline-related trimethylamine-containing compound in the subject's biological sample to a control value. The test subject's risk of having cardiovascular disease is then characterized as higher if the levels of the choline-related trimethylamine-containing compound are higher than the control value. Also provided are methods of identifying a subject at risk of experiencing a complication of atherosclerotic cardiovascular disease, and methods of evaluating the efficacy of a cardiovascular therapeutic agent in a subject with cardiovascular disease using levels of choline-related trimethylamine-containing compounds.

35. 发明授权

US11911399B2 Treating and preventing disease with TMA and TMAO lowering agents 有权
公开(公告)号：US11911399B2
公开(公告)日：2024-02-27
申请号：US17189551
申请日：2021-03-02
申请人： The Cleveland Clinic Foundation
发明人： Stanley L. Hazen
IPC分类号： A61K31/13 , A61K31/43 , A61P9/00 , A61P13/12 , A61K31/616 , A61K31/133 , A61K31/205 , A61K31/4164 , A61K31/4365 , A61K31/4709 , A61K31/496 , A61K31/519 , A61K31/675 , A61K31/409 , A61K33/44 , G01N33/49 , A61K31/00
CPC分类号： A61K31/616 , A61K31/00 , A61K31/13 , A61K31/133 , A61K31/205 , A61K31/409 , A61K31/4164 , A61K31/43 , A61K31/4365 , A61K31/4709 , A61K31/496 , A61K31/519 , A61K31/675 , A61K33/44 , A61P9/00 , A61P13/12 , G01N33/492 , G01N2800/32 , G01N2800/34 , G01N2800/52
摘要： Provided herein are compositions, systems, and methods for treating a disease, such as kidney and/or cardiovascular disease, with an agent that reduces the production of trimethylamine (TMA) or trimethylamine-n-oxide (TMAO) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (DMB) or a DMB derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (FMO3) inhibitor; iv) a gut TMA lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a TMA and/or TMAO sequestering agent.

36. 发明申请

US20210270855A1 PIP2 AS A MARKER FOR HDL FUNCTION AND CARDIOVASCULAR DISEASE RISK 有权
公开(公告)号：US20210270855A1
公开(公告)日：2021-09-02
申请号：US17203883
申请日：2021-03-17
申请人： The Cleveland Clinic Foundation
发明人： Jonathan D. Smith , Kailash Gulshan , Stanley L. Hazen
IPC分类号： G01N33/92 , C12N15/113 , G16H50/30 , G01N33/68 , A61K45/06 , C07K16/40
摘要： Provided herein are compositions, systems, kits, and methods for detecting cardiovascular disease, risk of cardiovascular disease, and/or reverse cholesterol transport potential in a subject based on the levels of PIP2 phospholipid in the subject.

37. 发明授权

US10983100B2 Trimethylamine-containing compounds for diagnosis and prediction of disease 有权
公开(公告)号：US10983100B2
公开(公告)日：2021-04-20
申请号：US16265571
申请日：2019-02-01
申请人： The Cleveland Clinic Foundation
发明人： Stanley L. Hazen , Zeneng Wang , Bruce S. Levison
IPC分类号： G01N33/68 , A61K31/4164 , A61K31/43 , A61K31/496 , A61K31/7036 , G01N30/72 , G01N30/88 , C12Q1/02 , C12Q1/18
摘要： The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two years, and/or three years). The present application also relates to the use of such markers and methods for monitoring the status of such diseases in a subject or the effects of therapeutic agents on subjects with such diseases.

38. 发明申请

US20200209264A1 PIP2 AS A MARKER FOR HDL FUNCTION AND CARDIOVASCULAR DISEASE RISK 审中-公开
公开(公告)号：US20200209264A1
公开(公告)日：2020-07-02
申请号：US16544356
申请日：2019-08-19
申请人： The Cleveland Clinic Foundation
发明人： Jonathan D. Smith , Kailash Gulshan , Stanley L. Hazen
IPC分类号： G01N33/92 , G01N33/68 , G16H50/30 , C12N15/113 , C07K16/40 , A61K45/06
摘要： Provided herein are compositions, systems, kits, and methods for detecting cardiovascular disease, risk of cardiovascular disease, and/or reverse cholesterol transport potential in a subject based on the levels of PIP2 phospholipid in the subject.

39. 发明申请

US20190257840A1 DETECTION OF GLUCURONIDATED AND 3-BROMOTYROSINE 审中-公开
公开(公告)号：US20190257840A1
公开(公告)日：2019-08-22
申请号：US16281811
申请日：2019-02-21
申请人： The Cleveland Clinic Foundation
发明人： Stanley L. Hazen , Zeneng Wang
IPC分类号： G01N33/68
摘要： The present invention relates to methods, kits, and compositions for: i) detecting the level of 3-bromotyrosine in a sample that has been treated to liberate 3-bromotyrosine from 4-O-glucuronide-3-bromotyrosine, and/or ii) detecting the level of 4-O-glucuronide-3-bromotyrosine, and/or the combined level of both 4-O-glucuronide-3-bromotyrosine and 3-bromotyrosine, in a sample that has not been treated to liberate 3-bromotyrosine from 4-O-glucuronide-3-bromotyrosine. In certain embodiments, such detected levels are used to: i) identify the presence, severity, or risk of an eosinophilic disorder (e.g., asthma or a TH2-high eosinophilic disorder); ii) identify therapy effective for treating asthma or an eosinophilic disorder; or iii) identify patients suitable for treatment with therapeutic agents targeted to asthma or an eosinophilic disorder.

40. 发明申请

US20170336425A1 PIP2 AS A MARKER FOR HDL FUNCTION AND CARDIOVASCULAR DISEASE RISK 审中-公开
公开(公告)号：US20170336425A1
公开(公告)日：2017-11-23
申请号：US15598522
申请日：2017-05-18
申请人： The Cleveland Clinic Foundation
发明人： Jonathan D. Smith , Kailash Gulshan , Stanley L. Hazen
IPC分类号： G01N33/92 , C12N15/113 , A61K45/06 , G06F19/00 , C07K16/40 , A61K39/00
CPC分类号： G01N33/92 , A61K45/06 , A61K2039/505 , C07K16/40 , C12N15/1137 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12Y301/03078 , G01N33/6893 , G01N2333/775 , G01N2405/06 , G01N2800/32 , G01N2800/50 , G16H15/00 , G16H50/30
摘要： Provided herein are compositions, systems, kits, and methods for detecting cardiovascular disease, risk of cardiovascular disease, and/or reverse cholesterol transport potential in a subject based on the levels of PIP2 phospholipid in the subject.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式